AKCA News
Archived Headlines
- US IPO Week Ahead: Two health care companies scheduled for a slow week 07/07/17
- US IPO Week Ahead: One biotech IPO scheduled for the short holiday week 06/30/17
- Biotechs stage comeback after slow quarter 04/13/17
- US IPO Weekly Recap: No IPOs, but 7 big filings feature Cloudera and Frontier Airlines 03/31/17
- Rare disease biotech Akcea Therapeutics files for a $100 million IPO 03/27/17
Renaissance Capital's 3Q17 US IPO Market Review
IPO Market Enters Fourth Quarter with the Wind at its Back The US IPO market saw 29 IPOs raise $4.1 billion in the third quarter, a drop from the prior year period. Small-cap health care companies, mostly biotechs, made up almost half of all...read more
US IPO Weekly Recap: Two IPOs start off the annual August lull
Two IPOs raised a combined $574 million this past week and notched modest gains. Pigments supplier Venator Materials raised $454 million and ultra-rare bone disease biotech Clementia Pharmaceuticals raised $120 million. July 2017 was the ...read more
US IPO Weekly Recap: 2 health care companies price, Snap breaks
Two health care companies priced their delayed IPOs this week to raise a combined $132 million. In other IPO news, Snap broke below its issue price and the pipeline saw new filings from a high-growth retailer and a fracker, along with an energy withdrawal. Six...read more
Lipid biotech Akcea Therapeutics prices upsized $125 million IPO at $8, below the range
Akcea Therapeutics, a late-stage biotech developing therapies for rare lipid disorders, raised $125 million by offering 15.6 million shares at $8, below the range of $12 to $14. It added 6.0 million shares to the offering to keep the deal size unchanged. Akcea...read more